COTY INC.
No enriched coverage for $COTY in the last 7 days.
No SEC Form 4 filings for $COTY in the last 30 days.
See all $COTY insider activity →Coty (NYSE: COTY) shares fell 6.8% in the afternoon after beauty-sector peers warned of weaker consumer demand. Galderma cited a slight softening in consumer sentiment and a potentially challenging second half, while Medmix reported a 9.2% decline in Beauty unit revenue for H1 2026. COTY was $2.55, down 18.2% YTD.
Reuters reports Coty will exit its Gucci Beauty licence a year early under a $400 million deal, returning the licence to Kering in mid-2027. Coty estimates it will forgo about $115 million annual adjusted EBITDA (15%), but expects $250 million upfront plus $150 million later to cut net debt (~$2.9B) and reduce costs. Barclays and analysts cite margin pressure but less Gucci dependence.
After the University of Michigan reported July Consumer Sentiment at 54.4, above the 51.0 forecast and February’s high, shares rose. The article links the gain to easing gasoline prices and improved index components. It highlights Coty (COTY) up 4.6%, Boston Beer (SAM) up 2.6%, and Zevia (ZVIA) up 1.5%, citing Coty’s YTD and 52-week figures.
Recent COTY coverage spans mergers & acquisitions, market movers and corporate actions.
The article frames today’s drop as read-through from peer commentary on consumer softness rather than a Coty-specific fundamental update.
Licence exit is a near-term earnings headwind but supports debt reduction, potentially shifting the risk profile toward leverage and margin recovery.
The move is framed as macro read-through to consumer staples demand, not a Coty-specific fundamental change.
Coty benefits from a large early-termination payment but faces reduced future Gucci-linked royalty exposure as the license is replaced.
Early Gucci license exit reduces uncertainty and brings upfront cash, but analysts flag a sizable FY28 EBITDA gap risk.
alphai scores every news story that mentions COTY with an AI model for sentiment and relevance, and aggregates insider trades from COTY INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Coty (NYSE: COTY) shares fell 6.8% in the afternoon after beauty-sector peers warned of weaker consumer demand. Galderma cited a slight softening in consumer sentiment and a potentially challenging second half, while Medmix reported a 9.2% decline in Beauty unit revenue for H1 2026. COTY was $2.55, down 18.2% YTD.
4 min readReuters reports Coty will exit its Gucci Beauty licence a year early under a $400 million deal, returning the licence to Kering in mid-2027. Coty estimates it will forgo about $115 million annual adjusted EBITDA (15%), but expects $250 million upfront plus $150 million later to cut net debt (~$2.9B) and reduce costs. Barclays and analysts cite margin pressure but less Gucci dependence.
5 min readAfter the University of Michigan reported July Consumer Sentiment at 54.4, above the 51.0 forecast and February’s high, shares rose. The article links the gain to easing gasoline prices and improved index components. It highlights Coty (COTY) up 4.6%, Boston Beer (SAM) up 2.6%, and Zevia (ZVIA) up 1.5%, citing Coty’s YTD and 52-week figures.
4 min readKering (PPRUY) said Gucci and L’Oréal (LRLCY) will start a 50-year exclusive beauty licensing deal in mid-2027, replacing Gucci’s current Coty (COTY) license that was set to run until June 30, 2028. Coty will receive about $400 million for early termination. Kering expects proceeds to support deleveraging after weaker performance, with net debt €9.5 billion at end-June 2025.
7 min readCoty Inc. said it will end its Gucci Beauty fragrance and license early, with L’Oréal taking over a 50-year exclusive beauty license effective mid-2027. Coty will receive about $400 million in two payments ($250 million this year, up to $150 million in 2027). Analysts at Jefferies and Barclays weigh impacts on Coty’s EBITDA estimates and note the next update is due with Q4 earnings.
7 min readCoty agreed to return the Gucci Beauty license to Kering about a year early for about $400 million, ending its current contract. Coty will use most proceeds to pay down debt and invest in brands like BOSS and Marc Jacobs. Deal terms include $250 million upfront, $150 million by Sept. 30, 2027, and up to $30 million incentives. Coty continues operating Gucci Beauty through June 30, 2027.
6 min readKering said Gucci’s beauty licensing deal with Coty ends early, with Coty paying about $400 million. Kering will receive payments in 2026 ($250 million) and 2027 (up to $150 million). L’Oréal’s new Gucci beauty license is expected to start mid-2027, following a 2025 framework for L’Oréal to buy Kering’s beauty division for 4 billion euros.
3 min readDow Jones headlines cover multiple corporate and market items. Coty will transfer the Gucci beauty license back to Kering ahead of schedule for $400 million; Kering plans a mid-2027 licensing deal with L’Oreal. Other stories include Momenta’s muted Hong Kong debut after a $751 million IPO, AstraZeneca’s $1.9 billion respiratory drug licensing deal, and stock moves for SpaceX, Amazon, Palantir, and Rivian.
2 min readDow Jones roundup covers multiple company-specific items: Coty to transfer Gucci Beauty license to Kering for $400M; Raytheon and NATO to study AMRAAM component suppliers in Europe; Amazon issues bonds; Shell sees higher trading results but lower gas output; Samsung expects record AI-chip quarter; Palantir expands into Mexico after a June stock drop; Rivian shares fall on a stock sale; Nokia surges on AI data-center pivot; LG Electronics forecasts profit jump.
6 min readCoty (NYSE: COTY) said it agreed with Kering to transition the Gucci Beauty license back to Kering about a year early. Coty will receive about $400 million, including $250 million at signing and $150 million by Sept. 30, 2027, plus a sale of inventory for the transition. Coty will run Gucci Beauty through at least June 30, 2027; proceeds will support debt paydown and reinvestment.
3 min read
